Takeaway
Although preliminary, the results of this study suggest that plexin D1-immunoglobulin G (D1-IgG) could be a potential biomarker for immunotherapy in patients with small fiber neuropathy (SFN).
Why this matters
SFN is characterized by neuropathic pain and autonomic symptoms, and in around half of the patients with this condition the cause is unknown.
The authors of this study have previously reported plexin D1-IgG in some patients with neuropathic pain and underlying neuroinflammatory diseases; in this study they provide further evidence for the role of antiplexin D1 antibodies in SFN.